---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-001757"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:57:42.249463+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Arrowhead amends bylaws to add proxy access, update stockholder nomination rules

## Summary
- Board adopted Second Amended and Restated Bylaws effective January 24, 2023.
- Adds proxy access: stockholder or group of up to 20 owning 3% for 3 years may nominate up to 20% of board or two directors.
- Updates procedural mechanics for stockholder nominations and business proposals.
- Requires a proxy card color other than white for stockholders soliciting proxies from others.
- Conforms bylaws to recent Delaware General Corporation Law amendments.

## SEC filing metadata
- accession: 0001628280-23-001757
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/0001628280-23-001757-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arwr-20230124.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-001757
- JSON: https://secwatch.observer/filing/0001628280-23-001757.json
- Plain text: https://secwatch.observer/filing/0001628280-23-001757.txt

## Key facts
- Governance Changes
  ARROWHEAD PHARMACEUTICALS, INC.: Amended and restated bylaws with updates including proxy access provisions, procedural mechanics, and conforming changes (effective 2023-01-24).
  - Change: bylaw amendment
  - Effective: 2023-01-24
  source text: On January 24, 2023, the Board of Directors (the “Board”) of Arrowhead Pharmaceuticals, Inc. (the “Company”) amended and restated the Company's Amended and Restated Bylaws (the “Second Amended and Restated Bylaws”), which became effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/0001628280-23-001757-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.